Registered Trials
-
NCT05069129
Phase 3United Arab Emirates
Total Enrollment: 1,848
Official Trial Registration:
-
NCT04869592
Phase 1/2China
Total Enrollment: 3,580
Official Trial Registration:
Vaccine Type: Protein Subunit
This vaccine may also be referred to as Recombinant COVID-19 Vaccine (CHO cell, NVSI-06-08)
This vaccine is approved.
United Arab Emirates
Total Enrollment: 1,848
China
Total Enrollment: 3,580
© 2022 VIPER Group COVID19 Vaccine Tracker Team
Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)
This site is provided for informational purposes only based on publically available data.